Section 5 – Corporate Governance and Management

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) On April 21, 2015, the Board of Directors of GenVec, Inc. (the “Company”) expanded the size of the Board of Directors by one director and appointed Michael Richman to fill the resulting vacancy. Mr. Richman’s term will expire at the 2015 annual meeting of stockholders of the Company.

Mr. Richman has been President and Chief Executive Officer of Amplimmune, a member of the AstraZeneca Group, since 2013. Prior to Amplimmune’s acquisition by AstraZeneca, he was president and then president and chief executive officer of Amplimmune when it was a privately-held biologics company focused on cancer and autoimmune diseases. From 2002 through 2007, he was the executive vice president and chief operating officer of MacroGenics, a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, autoimmune disorders and infectious diseases. Mr. Richman has more than 30 years of experience working in research, intellectual property and business development capacities. Mr. Richman is also member of the boards of directors of publicly-traded Opexa Therapeutics, Inc. and Pieris Pharmaceuticals, Inc. and privately-held Madison Vaccines Incorporated.

Mr. Richman is expected to be compensated according to the Company’s policy for non-employee directors, which is set forth under the heading Director Compensation Table in the Company’s definitive proxy statement for its 2014 annual meeting of stockholders. That description is incorporated in this Current Report by reference.